Protalix BioTherapeutics, Inc. announced today that Health Canada has granted regulatory approval to Elelyso (taliglucerase alfa for injection) for the long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. Elelyso may also be used for the hematological manifestations in pediatric patients with a confirmed diagnosis of Type 3 Gaucher disease.  Elelyso will be marketed in Canada by Pfizer Inc., the Company's commercialization partner.

For more details, go to: http://phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-newsArticle&ID=1935795&highlight=